← Back to Clinical Trials
Recruiting NCT06816303

NCT06816303 Patients With Diabetes Mellitus on Drug Treatment on the List or Already Undergoing Orthotopic Liver Transplantation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06816303
Status Recruiting
Phase
Sponsor IRCCS Azienda Ospedaliero-Universitaria di Bologna
Condition Diabetes Mellitus Type 2
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2021-11-19
Primary Completion 2025-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2021-11-19 with a primary completion date of 2025-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

observational study through which we aim to collect information on metabolic compensation, the degree of satisfaction with hypoglycemic therapy, the onset of complications of diabetes or liver disease, evaluation of survival, in patients on the list for at least three months or already undergoing liver transplantation for at least three months

Eligibility Criteria

Inclusion Criteria: * type 2 diabetes mellitus * presence on the list for OLT for at least 3 months or have already been submitted to OLT for at least 3 months * age ≥ 18 years * signature of written informed consent to participate in the observational study, either by the participant or legal guardian Exclusion Criteria: \- Pregnancy or breastfeeding

Contact & Investigator

Central Contact

Lucia Brodosi

✉ lucia.brodosi2@unibo.it

📞 +39 0512143248

Principal Investigator

Lucia Brodosi

PRINCIPAL INVESTIGATOR

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Frequently Asked Questions

Who can join the NCT06816303 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes Mellitus Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06816303 currently recruiting?

Yes, NCT06816303 is actively recruiting participants. Contact the research team at lucia.brodosi2@unibo.it for enrollment information.

Where is the NCT06816303 trial being conducted?

This trial is being conducted at Bologna, Italy.

Who is sponsoring the NCT06816303 clinical trial?

NCT06816303 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Lucia Brodosi at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology